



Continuing Medical Education
Yale CME

Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

Early detection of pancreatic cancer through precision medicine techniques

Louise L. Wang, MD
Gastroenterology Fellow, University of Pennsylvania

Tuesday, February 8, 2022
5:00 pm - 6:00 pm

<https://zoom.us/j/92508014539?pwd=Ulh2MCtnnd3JldEtUR0tVM3JxcVFKdz09>

Host: Loren Laine, MD
Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29434) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second most deadly cancer in the US population by 2030. While PDAC is potentially curable when caught locally, the majority of patients are diagnosed at advanced stages when medical therapies are limited, contributing to dire 5-year survival rates (~10%). Universal screening is infeasible, and screening has focused on hereditary cancers, overlooking the 90% of PDAC that is sporadic. Thus, there is an unmet need to identify the vast majority of sporadic cases of PDAC in the general population at operable stages to improve survival. **Objectives:** Identify the challenges of population-level screening for pancreatic cancer; Understand susceptibility to pancreatic cancer from clinical and genetic causes; Recognize the timely opportunity to improve pancreatic cancer risk prediction by (i) leveraging electronic health record-linked biobanks and (ii) existing prediction tools from other cancers. **Faculty Disclosures:** None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**